U.S. Replenishes COVID-19 Antibody and Oral Antiviral Supplies

The distribution process for COVID-19 therapeutics in the U.S. recently transitioned from an allocation process to one similar to the ordering process for vaccines.

This new U.S. HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) process, known as the 'threshold and replenishment' method, empowers state and territorial health department sites to continue ordering COVID-19 products.

Threshold quantities are determined by ASPR using the same methodology as previous allocations:

• The oral antivirals Paxlovid and Lagevrio threshold amounts are determined on a pro-rata population basis, and,
• The monoclonal antibodies (mAbs) Bebtelovimab threshold amounts are determined using a disease-based methodology, while Evusheld threshold amounts are determined on a pro-rata population basis, and replenishment occurs monthly. 

On May 9, 2022, the U.S. HHS/ASPR confirmed that about 29,000 additional mAbs doses would be distributed to states, territories, and related agencies this week.

Since Sept. 24, 2021, the U.S. government has distributed about 7.7 million mAbs.

And the ASPR will distribute Lagevrio (107,208) and Paxlovid  (Standard and Renal) (368,780) oral COVID-19 treatments this week.

The U.S. FDA has issued Authorizations for these COVID-19 products, which are available in most local pharmacies, clinics, and hospitals throughout the U.S. Various fees may apply to the administration of these products.

Note: The ASPR announcement was curated for mobile readership.